4 Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan
There is no penalty for moving slowly
Material Limitations of This Review
About 19 percent of companies with 200 or more workers, and 43 percent of firms with 5,000 or more workers, covered GLP-1 drugs for weight loss in their largest health plan in 2025, according to research from the Peterson Center on Healthcare and the Kaiser Family Foundation (KFF)
Furthermore, MC1R activation is thought to downregulate the mRNA expressions of liver cell transforming growth factor 1 (TGF-1), collagen 1, and various cell adhesion molecules, which are considered key contributors to fibrosis progression
Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]